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Abstract: Shatavari has long been used as an Ayurvedic herb for women’s health, but empirical 
evidence for its effectiveness has been lacking. Shatavari contains phytoestrogenic compounds that 
bind to the estradiol receptor. Postmenopausal estradiol deficiency contributes to sarcopenia and 
osteoporosis. In a randomised double-blind trial, 20 postmenopausal women (68.5 ± 6 years) in-
gested either placebo (N = 10) or shatavari (N = 10; 1000 mg/d, equivalent to 26,500 mg/d fresh 
weight shatavari) for 6 weeks. Handgrip and knee extensor strength were measured at baseline and 
at 6 weeks. Vastus lateralis (VL) biopsy samples were obtained. Data are presented as difference 
scores (Week 6—baseline, median ± interquartile range). Handgrip (but not knee extensor) strength 
was improved by shatavari supplementation (shatavari +0.7 ± 1.1 kg, placebo −0.4 ± 1.3 kg; p = 0.04). 
Myosin regulatory light chain phosphorylation, a known marker of improved myosin contractile 
function, was increased in VL following shatavari supplementation (immunoblotting; placebo −0.08 
± 0.5 a.u., shatavari +0.3 ± 1 arbitrary units (a.u.); p = 0.03). Shatavari increased the phosphorylation 
of Aktser473 (Aktser473 (placebo −0.6 ± 0.6 a.u., shatavari +0.2 ± 1.3 a.u; p = 0.03) in VL. Shatavari 
supplementation did not alter plasma markers of bone turnover (P1NP, β-CTX) and stimulation of 
human osteoblasts with pooled sera (N = 8 per condition) from placebo and shatavari supplemen-
tation conditions did not alter cytokine or metabolic markers of osteoblast activity. Shatavari may 
improve muscle function and contractility via myosin conformational change and further investi-
gation of its utility in conserving and enhancing musculoskeletal function, in larger and more di-
verse cohorts, is warranted.  
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1. Introduction 
Shatavari (Asparagus Racemosus Willd.) has long been used as an Ayurvedic herb for 
women’s health [1], but empirical evidence for its effectiveness remains limited. Steroidal 
saponins are thought to be the principal bioactive constituents of shatavari root. These 
saponins are known as shatavarins I–IV, and they are glycosides of sarsasapogenin [2]. 
Shatavari root also contains other chemical constituents of note, including racemosides, 
racemosol, racemofuran and asparagamine A, all of which display antioxidant activity 
[2]. The limited research that exists suggests that shatavari also contains phytoestrogenic 
compounds that are capable of binding to the estradiol (E2) receptors (E2R). Indeed, E2R 
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functionalised magnetic nanoparticles can isolate phytoestrogens of 4.6 nmol E2-equiva-
lent activity from a 1-mg crude extract of Asparagus racemosus [3]. The phytoestrogens that 
are most relevant to human health are those for which the following is the case: (1) they 
are distinct from structures that occur naturally in mammals; (2) they are contained in 
plants that are consumed by humans; and (3) they are bioavailable and capable of binding 
to human E2R [4]. Thus, the isoflavones genistein and daidzein, the coumestan coumes-
trol, the lignans enterolactone and enterodiol, the flavonols quercetin, kaempferol, rutin 
and the stilbene resveratrol represent the most prolific and relevant dietary forms of phy-
toestrogens in humans [4,5]. In silico research suggested that shatavari-derived phytoes-
trogens, including rutin, kaempferol, genistein, daidzein and quercetin, bind to E2R with 
greater affinity than a selective estrogen receptor modulator control, bazedoxifene [6].  
Shatavari administration in rats induces pro-estrogenic changes in mammary glands 
and genital organs [7]. Shatavari also appears to have galactogogue activity; in a placebo-
controlled study that administered 60 mg/kg/d shatavari root powder to breastfeeding 
mothers for 30 days, systemic prolactin concentrations were increased (three-fold) and 
shatavari promoted infant weight gain [8]. However, a similar study (in which the 
shatavari dose was unclear) found no effect on systemic prolactin concentrations [9]; both 
studies were of poor quality. The mechanism by which shatavari increases serum prolac-
tin concentration is unknown. Little is definitively known about how herbal galacta-
gogues act, beyond speculation that they have E2-like activity and rely upon phytoestro-
gen’s interaction with estrogen receptor alpha (Erα) [10,11].  
The potential for estrogen-like effects of shatavari supplementation has implications 
for both muscle and bone health after the menopause. Observational data have long sug-
gested that in women, post-menopausal estrogenic deficits may promote the age-associ-
ated decline in muscle strength and function (sarcopenia); men experience a more gradual 
decline in handgrip strength (HGS) across the lifespan, whereas women display a sharp 
decline in such strength in the middle of the sixth decade [12]. A large meta-analysis of 
studies that examined muscle strength and hormone replacement therapy (HRT) demon-
strated that HRT increases muscle strength [13]. E2 withdrawal has a detrimental effect 
on myosin binding function and, therefore, muscle force production; conversely, E2 im-
proves muscle force production, and may promote muscle protein synthesis [14–16]. One 
study showed that shatavari (500 mg·d−1 root extract; fresh weight equivalent not stated) 
enhanced strength gains in young men following eight weeks of bench press training [17]; 
this was an observational study with no indication of possible mechanisms of action. 
However, it does suggest that shatavari may be a beneficial ergogenic aid in supporting 
resistance training-induced increases in muscle size and strength; no assessment of these 
ergogenic effects has been made in older adults. 
The decreased E2 production that precipitates menopause is also associated with a 
decline in bone mineral density, a phenomenon that increases the risk of bone fractures 
[18]. Elderly individuals that experience a hip fracture have a three-fold increase in their 
risk of all-cause mortality [19]. HRT decreases the risk of osteoporosis and fractures [20]. 
Clinical trials that suggested limited therapeutic benefit of HRT and an increased risk of 
harm (breast cancer, cardiovascular disease) were recently reassessed and HRT was once 
again determined to have a clinical benefit and an acceptable safety profile; despite this, 
the uptake of HRT was found to have declined [20]. The reputational damage to HRT 
would appear to be such that evidence-based alternative therapeutic options for the pre-
vention of osteoporotic fracture in post-menopausal women are desirable and could have 
a tangible public health benefit, particularly given the ageing global population [21].  
E2, Erα and estrogen receptor beta (Erβ) are known to play a central role in bone 
maintenance and turnover. These are processes that are reliant on a dynamic equilibrium 
between osteoblast and osteoclast activity. Exogenous signals, e.g., mechanical loading, 
are sensed by osteocytes. In response, osteoblasts increase their receptor activator of nu-
clear factor κB ligand (RANKL) expression, which activates pre-osteoclast RANK recep-
tors, thus promoting mature osteoclast formation. Osteoclasts are activated to resorb bone, 
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via the production of hydrogen ions and lysosomal enzymes. At the conclusion of the 
resorption phase, osteoclasts undergo apoptosis and an osteogenic environment domi-
nates once more; crucially, osteoblasts express osteoprotegerin (OPG) in such an environ-
ment, which serves as a decoy to RANKL, thus limiting the binding of RANKL to its re-
ceptor RANK [22]. Broadly, E2 is thought to protect bone mass and architecture in the 
following ways: 1) by stimulating osteoclast apoptosis and inhibiting apoptosis in osteo-
blasts and osteocytes; 2) by repressing the production of pro-osteoclastic cytokines (e.g., 
interleukin 1 (IL-1), interleukin 6 (IL-6) and tumour necrosis factor alpha (TNFα)) by os-
teoblasts; and 3) by increasing the expression of OPG [18,23]. Many of these effects are 
thought to be mediated via the interaction of E2 with Erα [18].  
Given the phytoestrogen content of shatavari and evidence of its estrogen-like effects 
in vivo, we hypothesised that six weeks shatavari supplementation in postmenopausal 
women would induce increases in in vivo molecular markers of skeletal muscle contrac-
tility and protein synthesis. We further hypothesised that sera from shatavari-supple-
mented participants would promote a positive bone turnover phenotype in primary hu-
man osteoblasts in vitro. Secondarily, in this initial six-week supplementation study, we 
measured HGS and knee extensor strength, hypothesising that alterations in muscle con-
tractility might be evident in this timeframe.  
2. Materials and Methods 
2.1. Study Participants 
This double-blind, placebo-controlled parallel design study was approved by the 
University of Exeter’s Sport and Health Sciences Research Ethics Committee 
(190206/B/01). Participants were recruited via social media adverts and via the local chap-
ter of the University of the Third Age (convenience sampling). All participants gave writ-
ten informed consent to participate. Twenty-four postmenopausal women (≥60 years) 
were screened and recruited; 20 participants (68.5 ± 6 years, body mass index (BMI) 23.3 ± 
3.8) completed the study. In accordance with local ethical approval procedures, partici-
pants were free to withdraw without giving a reason; none were withdrawn due to an 
adverse event. Participants were pre-screened by telephone or email for self-reported ex-
clusion criteria. Exclusion criteria were: BMI > 30; last menstrual period < 12 months pre-
viously; use of estrogenic or progestogenic hormone replacement therapy via oral, trans-
dermal or subcutaneous implant routes in previous five years; diagnosis of osteoporosis 
or osteopenia; taking any medication for the prevention of osteoporosis, including 
bisphosphonates and non-bisphosphonates (e.g., raloxifene, denosumab, teriparatide or 
calcitriol). Calcium and vitamin D supplementation were permitted, but no participants 
reported taking such supplements. Although not an inclusion criterion, all participants 
completed an International Physical Activity Questionnaire (IPAQ)—Short Form as part 
of the participant screening process. All were classified as having ‘high’ levels of physical 
activity according to the evidence-based tool produced by di Blasio et al [24]. 
2.2. Study Design and Supplementation Protocol 
Participants attended a screening and consent visit during which eligibility was again 
confirmed and informed consent was obtained. Body weight and height were measured. 
Participants were familiarised with tests of HGS and leg strength, completing the full pro-
tocol described in subsequent sections. Participants returned for visit two having fasted 
overnight and abstained from caffeine consumption in the preceding 24 hours. They com-
pleted tests of HGS and leg strength. A blood sample was obtained via venepuncture and 
a Vastus lateralis (VL) skeletal muscle biopsy was performed. A researcher who was not 
involved in data collection or analysis randomised participants to receive either placebo 
or shatavari supplementation for six weeks using a random number generator. Partici-
pants consumed two capsules per day containing either placebo (magnesium stearate, 500 
mg/capsule) or shatavari (500 mg powder/capsule equivalent to 13,250 mg fresh weight 
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shatavari root). The capsules were visually identical and did not have an odour. Compli-
ance was assessed by providing an excess of capsules and counting the number that re-
mained at the end of the study period. No participant missed more than 3/42 doses over 
the six-week supplementation period, with 11/20 participants returning the correct num-
ber of capsules. Visit three took place six weeks after visit two; the study protocol was 
repeated as before.  
2.3. Measurement of Handgrip Strength 
HGS was measured using a handgrip dynamometer according to the Southampton 
Protocol [25]. Participants sat in a standard chair and rested their forearms on the armrest. 
The wrist was positioned just over the end of the armrest, in a neutral position with the 
thumb facing upwards. Each hand was tested three times and the tested hand was alter-
nated. The best score for either hand was used for data analysis. One participant reported 
an injury to their dominant limb during the supplementation period. Their best efforts 
with their non-dominant limb were included in the data analysis.  
2.4. Lower Limb Dynamometry 
Assessment of lower limb knee extensor muscle strength was performed using an 
isokinetic dynamometer (Biodex System 3; Biodex Medical Systems, New York, NY, 
USA). At the familiarisation visit, participant, chair and dynamometer positioning were 
personalised, such that the participants sat in the chair with the ankle of their dominant 
leg fixed to the knee extensor attachment, knee joint in-line with the dynamometer pivot 
point. Leg dominance was established by asking participants which leg they would pref-
erentially use to kick a ball. Participants’ lower backs were in contact with the chair 
backrest, which was positioned such that the posterior aspect of their knee had approxi-
mately 2 cm clearance from the edge of the seat. Participants were strapped into the chair 
and instructed to complete all movements with their arms folded across their chests, to 
isolate the knee extensor effort. All isokinetic movements took place over a range of mo-
tion of 80 ° from full flexion + 1 ° at the knee, at 60 °·s-1 for both the concentric and eccentric 
phases. A warmup consisting of five sets of five concentric repetitions (1 min rest between 
sets) was conducted, with participants instructed to complete this at 50% effort. Following 
the familiarisation visit, a limit of 60% isometric maximum voluntary contraction (MVC) 
was placed on these sets, such the dynamometer would stop a repetition if too much effort 
was produced. Participants then completed three sets of three maximal isokinetic repeti-
tions (concentric and eccentric effort; 1 min rest between sets). Following this, the knee 
was fixed at 90 ° of flexion and three MVCs were performed, separated by 1 min of rest. 
Force data were recorded and analysed in Spike2 ver.6 software (CED, Cambridge, UK). 
The best MVC, concentric isokinetic and eccentric isokinetic values attained were used for 
analysis.  
2.5. Blood Sampling and Analysis of Bone Turnover Markers 
Antecubital venous blood samples were collected into serum separator (SST) and 
lithium heparin (LH) containing vacutainer tubes. LH tubes were centrifuged at 4500 rpm 
for 15 minutes at 4 °C; plasma samples were aliquoted into microcentrifuge tubes. SST 
tubes were maintained at room temperature for 30 min prior to centrifugation at 4500 rpm 
for 15 min at 4 °C; serum was aliquoted into microcentrifuge tubes. Plasma and serum 
samples were stored at – 80 °C until analysis. Carboxy-terminal cross-linking telopeptide 
of type I collagen (β-CTX) and procollagen type I N-terminal propeptide (P1NP) were 
quantified using electrochemiluminescence immunoassay on a Cobas e601 analyser 
(Roche Diagnostics, Mannheim, Germany), performed at the Bioanalytical Facility, Uni-
versity of East Anglia. The interassay coefficient of variation (CV) for β-CTX was < 3% 
between 0.01 and 6.0 µg/L, with a sensitivity of 0.01 µng/L. The inter-assay CV for P1NP 
was < 3% between 5 and 1200 µg/L, with a sensitivity of 5 µg/L. 
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2.6. Vastus Lateralis Biopsy 
VL muscle biopsy samples were taken from the exercised (dominant) leg using the 
suction-modified percutaneous Bergstrom needle technique [26]. The leg from which the 
biopsy was taken was sterilised with povidone-iodine 10% w/w cutaneous solution 
(Ecolab, Northwich, UK) and anaesthetised by infiltration of the skin and subcutaneous 
adipose tissue with 2% lidocaine (B Braun, Sheffield, UK). An incision of approximately 
0.8 cm was made, and skeletal muscle (~150 mg) collected. The incision was closed with 
adhesive butterfly stitches and covered with a waterproof dressing. Skeletal muscle was 
dissected free of any obvious blood and adipose tissue and immediately snap frozen in 
liquid nitrogen. Muscle samples were stored at – 80 °C until analysis. 
2.7. Immunoblotting 
Detailed immunoblotting methods are provided in the Supplementary Material 
(Supplementary Methods, Supplementary Materials Table S1). Quantifications of protein 
phosphorylation were normalised to total protein signal. To ensure the veracity of the 
phosphorylation signals obtained, the same blots were not stripped and re-probed for to-
tal and phosphorylated forms of a given protein, rather the electrophoresis and blotting 
was repeated. Samples were quantified in duplicate. Blot images were never adjusted to 
manipulate brightness/contrast, except for Coomassie stained blots, where minor adjust-
ments were made and applied across all lanes. 
2.8. Primary Human Osteoblast Cell Culture 
Six femoral heads were obtained via the Royal Devon and Exeter Tissue Bank (ethical 
approval RDETB-REC no 6/SC/0162), which is managed within the NIHR Exeter Clinical 
Research Facility. Femoral head donors were postmenopausal women (73 ± 9.9 years BMI 
29.6 ± 8.6) undergoing hip replacement. Exclusion criteria were: last menstrual period < 
12 months previously; use of estrogenic or progestogenic hormone replacement therapy 
via oral, transdermal or subcutaneous implant routes in previous five years; diagnosis of 
osteoporosis or osteopenia; taking any medication for the prevention of osteoporosis, in-
cluding bisphosphonates and non-bisphosphonates (e.g., raloxifene, denosumab, teripar-
atide or calcitriol). Calcium and vitamin D supplementation were permitted. Bone chips 
were removed from the subchondral region using a Friedman Rongeur and were washed 
five times in PBS containing 100U/mL penicillin streptomycin. Bone chips were removed 
to 25 cm2 vented flasks containing osteoblast differentiation media: Dulbecco’s Modified 
Eagle Medium (DMEM) High Glucose (D6546, Merck, Gillingham, UK) 10% Fetal Bovine 
Serum (FBS) (qualified E.U.-approved, South-American origin) (10270106, GIBCO, Wal-
tham, MA, USA), 100 Units/mL Penicillin/streptomycin (15070-063, GIBCO), 2mM L-Glu-
tamine, G7513 (Merck), 1% Minimum Essential Medium (MEM) non-essential amino ac-
ids (11140050, GIBCO, Waltham, MA, USA), β-glycerophosphate disodium salt hydrate ( 
2mM) (G9422, Merck, Gillingham, UK), L-Ascorbic acid (50 µg/ml) (A4403, Merck, Gil-
lingham, UK), Dexamethasone (10 nM) (D4902, Merck, Gillingham, UK). Bone chips were 
cultured in a humidified incubator (37 °C, 5% CO2). Media were changed after five days 
and every three days thereafter, with bone chips being removed when osteoblast coverage 
reached approximately 30%.  
2.9. Assessment of Osteoblast Differentiation  
Osteoblasts were seeded at 6x103 cells per well in a 24-well plate and fed with osteo-
blast differentiation media containing Primary human osteoblasts were stimulated for 14 
days with sera (10% v/v in osteoblast differentiation medium) pooled from eight partici-
pants in each supplementation group (baseline and six-week timepoints). A 10% FBS con-
dition was included in each experiment as a previously established control to demonstrate 
effective differentiation [27]. Osteoblasts were fed by 1:2 demi depletion on days 3, 6, 9 
and 12; the experimental endpoint was day 14. All experiments were conducted in four to 
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six biological replicates, with triplicate technical replicates (wells) stimulated with each 
serum condition for each biologically independent culture. Supernatants were retained 
for the quantification of protein secretion.  
2.10. Osteoblast Cytokine Secretion 
Macrophage colony stimulating factor (M-CSF), osteoprotegerin (OPG), IL-6 and IL-
1β were quantified using enzyme-linked immunosorbent assays (ELISA) according to the 
manufacturer’s instructions (see Supplementary Materials Table S2).  
2.11. Osteoblast Bone Nodule Formation 
Osteoblast bone nodule formation was quantified via alizarin red staining at day 14 
of differentiation. Following removal of the supernatants, osteoblasts were washed three 
times in phosphate buffered saline (PBS) and were stained with alizarin red staining so-
lution (0.5% w/v alizarin red (Merck, Gillingham, UK) in 1% ammonia solution, pH 4.5) 
for 10 min at room temperature. Osteoblasts were again washed three times in PBS and 
were then incubated in 10% w/v cetyl pyridinium chloride (C0732, Merck, Gillingham, 
UK; warmed to 37 °C) for 10 min at room temperature. This supernatant was further di-
luted 1:10 in 10% w/v cetyl pyridinium chloride (warmed to 37°C) and the absorbance of 
100 µL of each solution was quantified in duplicate at 550nm on a microplate reader (BMG 
LABTECH, Aylesbury, UK). 
2.12. Osteoblast Metabolism  
Osteoblast metabolism was quantified at day 14 of serum stimulation via an alkaline 
phosphatase (ALP) activity assay. Osteoblasts were lysed in radioimmunoprecipitation 
assay (RIPA) buffer and lysates were diluted 1:4 with 1mM MgCl2. Seven alkaline phos-
phatase standards (3 units/mL top standard, serially diluted 1:2 in 1:4 RIPA:1 mM MgCl2) 
were prepared from a stock solution (Human placenta alkaline phosphatase, P3895, 
Merck, Gillingham, UK). Ten microlitres of sample or standard was added to a 96 well 
plate in duplicate and 100µL alkaline phosphatase substrate (P7998, Merck, Gillingham, 
UK) added per well and incubated at 37°C for 15 min. The reaction was stopped by the 
addition of 0.1N NaOH and the absorbance of each well was measured at 405 nm. ALP 
concentrations were calculated from the standard curve and corrected for the dilution in 
MgCl2. The protein concentration of the lysates was quantified via bicinchoninic acid 
(BCA) assay and alkaline phosphatase activity expressed per unit protein.  
2.13. Osteoblast Proliferation 
Osteoblast proliferation was quantified via a colourimetric tetrazolium salt-based cell 
proliferation assay (MTS assay; CellTiter 96® Aqueous One Solution; Promega, Madison, 
WI, USA). Osteoblast proliferation was assessed at two-day intervals for six days. Osteo-
blast differentiation medium was replaced with 100 µL serum-free differentiation me-
dium to prevent FBS interference with absorbance readings [28]. Twenty microliters of 
MTS reagent was added to each well the plate was incubated at 37 °C, 5% CO2 for 3 h. 
Each condition was assayed in triplicate. The absorbance of each well was quantified at 
450 nm using an absorbance microplate reader. 
2.14. Statistical Analyses 
Using standard deviations derived from unpublished immunoblotting data from 
older adults, we calculated that we required 10 participants per group to be able to detect 
a 1.6-fold change in myogenin protein expression; we recruited 12 participants per group 
to account for dropouts. Given the evidence from the literature of an effect of HRT on 
myogenin expression, and the lack of evidence regarding the effects of shatavari in skele-
tal muscle, myogenin expression was originally designated as our primary outcome meas-
ure. However, the shutdown of our lab facility due to the Covid-19 pandemic led to the 
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loss of a large number of consumables, including the degradation of many of our im-
munoblotting antibody stocks that required extensive subsequent troubleshooting. De-
spite myogenin expression being the designated primary outcome measure, we were 
forced to use our limited muscle sample stocks to quantify outcomes that required less 
extensive troubleshooting. Data are largely quoted mean differences (pre-supplementa-
tion to post-supplementation change) for both placebo and shatavari conditions, which 
were analysed by means of an unpaired t-test comparison of difference scores, and they 
are presented as mean ± standard deviation. Where there existed non-normal distribu-
tions, unequal variances or ‘outlier’ data points data were analysed by Mann–Whitney U 
test and are presented as median ± interquartile range of difference scores. Data were an-
alysed using GraphPad Prism v5.03 (GraphPad Software, San Diego, CA, USA). Shapiro–
Wilk tests were used to evaluate the normality of data sets and the Levene test was em-
ployed to assess the equality of variances within data groups. Outlier data were not ex-
cluded. A p-value of < 0.05 was considered statistically significant.  
3. Results 
3.1. Participant Baseline Characteristics  
Participant baseline characteristics are outlined in Supplementary Materials Table 
S3. There were no significant baseline age, BMI or strength differences between the sup-
plementation groups. We also note that two dropouts occurred per group and, even with 
a ‘second pass’ following a failed biopsy, we had a muscle tissue extraction failure rate of 
7.5% in this population, 
3.2. Shatavari Supplementation Improves Handgrip, but not Knee Extensor Strength in Post-
menopausal Women 
Six weeks of shatavari supplementation improved HGS in this cohort (placebo 0.4 ± 
1.3 kg, shatavari +0.7 ± 1.1 kg; p = 0.04, Mann–Whitney U, Figure 1A). Knee extensor iso-
metric (placebo 0 ± 7.8 N, shatavari -4.8 ± 6 N; p = 0.14, t-test), concentric (placebo +4.9 ± 
10.2 N, shatavari +0.96 ± 6.8 N; p = 0.33, t-test), and eccentric (placebo +2.9 ± 12.1 N, 
shatavari +5.1 ± 10.7 N; p = 0.67, t-test) strength were not altered by supplement condition 
(Figure 1B–C). 
 
Figure 1. Shatavari supplementation improves handgrip, but not knee extensor strength in post-
menopausal women. Postmenopausal women were supplemented with placebo (N = 10) or 
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shatavari (N = 10) for six weeks. Handgrip strength (A), isometric (B), concentric (C) and eccentric 
(D) knee extensor strength were measured at baseline and at six weeks. Data are presented as dif-
ference scores with the median ± interquartile range (A, outlier present) or mean ± standard devia-
tion (B–D) of these differences. * p < 0.05. 
3.3. Shatavari Supplementation Increases Vastus Lateralis Myosin Regulatory Light Chain Phos-
phorylation in Postmenopausal Women 
Myosin regulatory light chain phosphorylation (pMLC) was quantified via im-
munoblotting and was increased in VL following six weeks of shatavari supplementation 
(placebo -0.08 ± 0.5 arbitrary units (a.u)., shatavari +0.3 ± 1 a.u.; p = 0.03, Mann–Whitney 
U) (Figure 2). An additional panel demonstrating the spread of data with the lowest data-
point in the placebo dataset removed can be found in the Supplementary Material (Figure 
S1).  
 
Figure 2. Shatavari supplementation increases Vastus lateralis myosin regulatory light chain phos-
phorylation. Postmenopausal women were supplemented with placebo (N = 10) or shatavari (N = 
10) for six weeks. Total myosin regulatory light chain (MLC) and myosin regulatory light chain 
phosphorylation (pMLC) were quantified via immunoblotting at baseline and at 6 weeks. Samples 
were assayed in duplicate. Full versions of these immunoblots are found in Supplementary Material 
Figure S2. Data are presented as difference scores with the median ± interquartile range of these 
differences. Missing data are accounted for by failed muscle biopsy/biopsy sample of insufficient 
quantity. * p < 0.05. 
3.4. Shatavari Supplementation has an Equivocal Effect on Vastus Lateralis Protein Synthetic 
Pathways  
The phosphorylation status of protein synthetic pathway effectors was quantified via 
immunoblotting at baseline and following six weeks of shatavari supplementation. 
Shatavari increased the phosphorylation of Aktser473 (placebo -0.6 ± 0.6 a.u., shatavari +0.2 
± 1.3 a.u; p = 0.03, Mann–Whitney U). The phosphorylation of p70S6kThr389, 
4EBP1Thr37/46,S6Ser240/244 did not differ between conditions (Figure 3). 




Figure 3. Shatavari supplementation has an equivocal effect on Vastus lateralis protein synthetic 
pathways. Postmenopausal women were supplemented with placebo (N = 10) or shatavari (N = 10) 
for six weeks. Phosphorylation of Aktser473 p70S6kThr389, 4EBP1Thr37/46,S6Ser240/244 were 
quantified via immunoblotting at baseline and at six weeks. Samples were assayed in duplicate. Full 
versions of these immunoblots are found in Supplementary Materials Figure S3. Data are presented 
as difference scores with the median ± interquartile range (A,C,D) or mean ± standard deviation (B) 
of these differences. (E) Immunoblotting. * p < 0.05. Missing data are accounted for by failed muscle 
biopsy/biopsy sample of insufficient quantity. 
3.5. Shatavari Supplementation Does Not Alter In Vivo or In Vitro Markers of Bone Turnover 
Plasma concentrations of bone turnover markers P1NP and β-CTX were quantified 
at baseline and following six weeks of shatavari supplementation. Neither P1NP (placebo 
-0.4 ± 8.7 µg/L, shatavari + 1.3 ± 6.5 µg/L; p = 0.16, t-test), nor β-CTX (placebo +0.01 ± 0.11 
µg/L, shatavari -0.08 ± 0.22 µg/L; p = 0.27, Mann–Whitney U), were altered by supplemen-
tation condition (Figure 4 A, B). Primary human osteoblasts (N = 6) were stimulated for 
14 days with sera (10% in osteoblast differentiation medium) from participants in both 
supplementation groups (baseline and six-week timepoints). Supernatant concentrations 
of osteoblast-produced endocrine/paracrine cytokines were quantified by ELISA. Concen-
trations of OPG (placebo +0.24 ± 2.61 ng/mL, shatavari + 0.01 ± 2.94 ng/mL; p = 0.89, t-test), 
M-CSF (placebo +55.7 ± 100.5 ng/mL, shatavari -4.7 ± 67.0 µg/L; p = 0.25, t-test), IL-6 (pla-
cebo +58.8 ± 284.9 pg/mL, shatavari +189.6 ± 344.5 pg/mL; p = 0.39, Mann–Whitney U) and 
IL-1β (placebo -8.0 ± 20.4 ng/mL, shatavari +5.8 ± 12.3 ng/mL; p = 0.19, t-test) were not 
altered by supplementation condition (Figure 4 C–F). TNFα could not be detected.  




Figure 4. Shatavari supplementation does not alter plasma markers of bone turnover or osteoblast 
cytokine secretion. Postmenopausal women were supplemented with placebo (N = 10) or shatavari 
(N = 10) for six weeks. Plasma concentrations of bone turnover markers Procollagen 1 Intact N-
Terminal Propeptide (P1NP, A) and beta-C-terminal telopeptide (β-CTX, B) were quantified at base-
line and following six weeks of supplementation. Primary human osteoblasts were stimulated for 
14 days with sera (10% in osteoblast differentiation medium) pooled from eight participants in each 
supplementation group (baseline and six-week timepoints). Supernatant concentrations of osteo-
blast-produced endocrine/paracrine cytokines were quantified by ELISA. C) osteoprotegerin (OPG); 
D) macrophage colony stimulating factor (M-CSF); E) interleukin 6 (IL-6); F) interleukin 1 beta (IL-
1β). Data are presented as difference scores with the median ± interquartile range (B,D) or mean ± 
standard deviation (A,C,E,F) of these differences. 
Alkaline phosphatase activity was quantified as an indicator of osteoblast biosyn-
thetic activity, with no difference between supplementation conditions being observed 
(placebo -0.01 ± 0.31 units activity/mg protein, shatavari +0.04 ± 1.80 µg/L; p = 0.22, Mann–
Whitney U) (Figure 5 A). MTS assay of proliferating osteoblasts showed that there was no 
significant difference in mean MTS absorbance between supplementation conditions (F(3, 
24) = 1.027, p = 0.42) (Figure 5 B). Alizarin red staining detected no difference in osteoblast-
produced calcium deposits between the placebo and shatavari sera conditions (absorb-
ance change pre to post: placebo +0.07 ± 0.40, shatavari +0.07 ± 0.58; p = 0.22, Mann–Whit-
ney U) (Figure 5 C). No difference between supplementation conditions was observed for 
the expression of protein markers of osteoblast differentiation (Figure 5D–F). 




Figure 5. Shatavari-supplemented sera do not alter osteoblast metabolic activity or differentiation. 
Primary human osteoblasts were stimulated with sera (10% v/v in osteoblast differentiation me-
dium, 14 days for all except B, which underwent 6 days of stimulation) pooled from eight partici-
pants in each supplementation group (shatavari/placebo, baseline and six-week timepoints). (A) Al-
kaline phosphatase activity; (B) cellular proliferation rate; (C) bone nodule formation (alizarin red-
stain intensity); and (D–F) differentiation markers (Col1a1, RUNx2) were quantified. Data are pre-
sented as difference scores with the median ± interquartile range (A–D) or mean ± standard devia-
tion (D,E) of these differences. 
4. Discussion 
This is the first study to assess the effect of shatavari on skeletal muscle function in a 
cohort of older adults and the first offer insights into the molecular changes that may un-
derpin its functional effects. To our knowledge, this is also the first study to assess the 
effect of shatavari supplementation on markers of bone turnover. Six weeks of shatavari 
supplementation improved HGS in this cohort of postmenopausal women. Although no 
improvement in knee extensor strength was found, we demonstrated an increase in pMLC 
within the VL. We also demonstrated an increase in AktSer473 phosphorylation, although no 
alteration in phosphorylation status of other major effectors of muscle protein synthesis 
(p70S6kThr389, 4EBP1Thr37/46, S6Ser240/244) was observed. We did not find any effect of shatavari-
supplemented sera on markers of primary human osteoblast function.  
An increase in HGS and pMLC over a period of six weeks is congruent with what is 
known about the effect of E2 and pMLC on muscle strength. Such phosphorylation mod-
ulates striated muscle contraction by promoting movement of the myosin head towards 
the thin filament, thus increasing the probability of myosin interaction with actin [29–31]. 
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Age-dependent reductions in pMLC have been documented and appear to particularly 
affect women [32,33]. Our observation that shatavari increased pMLC and muscle 
strength over six weeks is consistent with the time course of such changes documented 
elsewhere; Lai et al. showed that E2 administration over 4-6 weeks rescued extensor dig-
itorum longus and soleus pMLC and force generation in bilaterally ovariectomized mice 
[34]. Further, deletion of ERα reduces muscle contractility and force production in female 
mice [35]. More work is required to definitively establish the link between shatavari-in-
duced pMLC changes and human skeletal muscle contractility, e.g., via the ex vivo assess-
ment of muscle fibre contractility and using in vivo techniques such as peripheral nerve 
stimulation and transcranial magnetic stimulation to assess central drive, excitability and 
muscle contractility. 
Perhaps surprisingly in the context of the shatavari-induced changes in HGS, knee 
extensor strength was not increased despite an increase in VL pMLC. Our subjective ex-
perience during this study was that the learning effect of our familiarisation session for 
this older adult cohort was not as effective as the same familiarisation protocol that we 
use regularly in younger cohorts. Indeed, there may be greater variability in reaching 
maximum voluntary activation in older age and our ‘best of three’ approach to such tests 
[36] may need to be modified in such cohorts to take the best value from a greater number 
of attempts [37]. Testing of HGS is an inherently more ‘accessible’ movement for those 
unfamiliar with resistance exercise and our a priori decision to use the best value from all 
six trials (three dominant, three non-dominant), in accordance with the ‘Southampton 
Protocol’ for such testing, may have mitigated this variability [25]. Indeed, the CV for the 
best HGS scores achieved at visits 2 and 3 for the placebo group was 2.9 ± 2.3%; the CV 
for the best MVC value was 4.1 ± 4%, although this did not reach statistical significance (p 
= 0.46, t-test). Notably the CVs for concentric (8.2 ± 6.5%) and eccentric (6.6 ± 4.1%) isoki-
netic measures of muscle strength were significantly larger than that for HGS (p = 0.03, t-
test for both). The lack of a forearm skeletal biopsy in the context of our HGS observations 
is unfortunate; however, the VL remains the most accessible skeletal muscle for biopsy 
outside of a secondary/tertiary medical care facility [38]. 
Intriguingly, we also observed an increase in AktSer473 phosphorylation, but no alter-
ation in phosphorylation status of other major effectors of muscle protein synthesis sig-
nalling. Interestingly in the context of this increase in AktSer473 phosphorylation, it was sug-
gested that one way in which pMLC may be increased is via the PI3K/MAPK/Akt/MLCK 
pathway [34]. However, no definitive activation of the proteins downstream of mTOR 
was observed. We note, however, that our analysis of p70S6kThr389 showed an increase in 
its expression with shatavari supplementation with p = 0.09. We do not consider non-sig-
nificant results such as this worthy of excessive weighting in a discussion of results or in 
the drawing of conclusions. However, we highlight this result in the context of the rela-
tively low number of viable biopsy samples that were available for analysis. We powered 
our analyses (using standard deviations derived from unpublished immunoblotting data 
from older adults) to be able to detect a 1.6-fold change in protein expression with 10 par-
ticipants per group; we recruited 12 participants per group to account for dropouts (two 
dropouts occurred per group) and biopsy failures. However, even with a ‘second pass’ 
following a failed biopsy, we had a muscle tissue extraction failure rate of 7.5% in this 
population; thus, these analyses did not have the statistical power that we had anticipated. 
Work published since the conception of our study has shown that c. 40% of healthy older 
female participants are at risk of a failed muscle biopsy. Wilson et al. highlighted low 
muscle mass as the principal contributor to this failure [39]. Our samples also often con-
tained a high proportion of subcutaneous or intramuscular adipose tissue, which accu-
mulates in skeletal muscle with advancing age [40]. Despite these caveats, we demon-
strated novel functional effects of shatavari supplementation in skeletal muscle, along 
with some important mechanistic insights. We consider that the potential for shatavari 
supplementation to enhance muscle protein synthesis should be further explored in 
longer-term resistance training studies, given our evidence of AktSer473 phosphorylation 
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following shatavari supplementation, coupled with the observations of Anders et al. that 
shatavari enhanced strength gains in young men following eight weeks of bench press 
training [17]. Indeed, the balance of current evidence suggests that E2 increases the ana-
bolic response to exercise over the longer term (for an excellent review, see [41]. It remains 
to be seen what sex differences exist in the effect of shatavari on skeletal muscle function. 
The work of Anders et al. suggests that its effects are not limited to the female sex, despite 
the primacy of testosterone and its derivatives as endocrine determinants of male skeletal 
muscle function [42]. It should be borne in mind that shatavari also contains steroidal sap-
onins, racemosides, racemosol, racemofuran and asparagamine A; little is known about 
their effects on skeletal muscle. We did not carry out a detailed analysis of the supplement 
used in this study; however, having established promising biological actions of this ‘off 
the shelf’ form of the supplement, we recommend that this analysis should be conducted 
for future work. This will allow researchers to begin to disentangle complex issues such 
as the constituents of shatavari that are responsible for its effects in vivo and will facilitate 
a more standardised approach to research into its effects (e.g., dosing).  
Indeed, the chemical complexity of shatavari and its metabolism in vivo is another 
area that warrants extensive further research. Determining the constituents of shatavari 
that evoke physiological responses is not a simple task. The bioavailability of phytoestro-
gen-containing supplements is variable and poorly understood. The intestinal flora pro-
duce both aglycone primary metabolites and secondary metabolites that potentially have 
a greater affinity for E2R than their parent compounds [43]. Indeed, this is why primary 
human osteoblasts in this study were treated with sera from women who had supple-
mented with placebo or shatavari for six weeks, with their final dose taken one hour prior 
to venepuncture (i.e., an acute-on-chronic serum supplementation condition). In vitro 
studies of bioactive supplements almost universally apply extracts of the supplements 
directly to cell cultures. For the reasons outlined above, we consider this approach to be 
inappropriate and lacking in physiological relevance.  
The decrease in E2 production that potentiates sarcopenia in women after the meno-
pause is also associated with a decline in bone mineral density. Given this observation, 
we also examined systemic and in vitro markers of bone turnover. Here, we utilised a 
previously established model for assessing metabolic activity and bone nodule formation 
in human primary osteoblasts [27]. We did not find any effect of shatavari-supplemented 
sera on markers of primary human osteoblast function, neither did we observe any 
changes in the osteoblast secretion of cytokines that are known to alter osteoclast activity. 
In this six-week supplementation study, these in vitro assays of bone turnover activity 
were the bone outcomes of primary interest and considered the most likely to be altered 
by supplement condition. However, we also quantified in vivo markers of bone turnover 
(P1NP and β-CTX), with no effect of supplementation being observed. Given the in vitro 
results that we describe, this is most likely due to a genuine lack of effect on shatavari on 
bone turnover. However, despite considerable efforts, in vitro models cannot perfectly 
reproduce human physiology and it remains possible that shatavari supplementation 
could have an effect on bone turnover in the longer term. Transdermal E2 treatments do 
induce changes in such markers over a similar timeframe. However, within-subject vari-
ability for these measures can be high (least significant change P1NP 21%, β-CTX 132%) 
[44] and the potency of any effect of shatavari on such measures might be expected to be 
less than pharmacological doses of E2.  
5. Conclusions 
Here, we examined the potential benefits of shatavari supplementation for the mus-
culoskeletal system after the menopause and this initial study signposted several novel 
effects and promising avenues for further research in this area. Discussion of the limita-
tions of our approach and conclusions was integrated into the main discussion; however, 
we note here that this study was conducted in a small cohort of physically active, healthy 
older women and further research is required to confirm these findings and to ascertain 
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their generalisability. Specifically, we found that shatavari appears to improve muscle 
function, potentially mediated by improvements in myosin contractility, and further in-
vestigation of its utility in conserving musculoskeletal function in older adults is war-
ranted. Further, the constituents of shatavari that mediate these effects (estrogenic or oth-
erwise) require identification. 
Supplementary Materials: The following are available online at www.mdpi.com/arti-
cle/10.3390/nu13124282/s1, Table S1: Immunoblotting antibody details, Table S2: ELISA details, Ta-
ble S3: Participant baseline characteristics, Figure S1. Shatavari supplementation increases Vastus 
lateralis myosin regulatory light chain phosphorylation in postmenopausal women. Postmenopau-
sal women were supplemented with placebo (N = 10) or shatavari (N = 10) for 6 weeks, Figure S2. 
Full versions of myosin light chain immunoblots presented in the manuscript, Figure S3. Full ver-
sions of other immunoblots presented in the manuscript. 
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